市值重回4000亿,但恒瑞医药还没有赢

医曜
Aug 22

本文系基于公开资料撰写,仅作为信息交流之用,不构成任何投资建议。一千个人眼中有一千个哈姆雷特,不同投资者眼中也有迥异的恒瑞医药。尤其是过去三年,恒瑞医药逐步淡化“孙飘扬”的烙印,以更加现代化的思维去拥抱市场。三年前的恒瑞医药,是资本市场公认的“医药茅台”——它坚持自主研发,对BD交易嗤之以鼻;创始人孙飘扬更是曾骄傲地表示“不从市场拿钱”,将分红视为对股东的最大回馈。三年后的今天,恒瑞医药刚刚创下...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10